Heart disease remains the leading cause of death in the United States, claiming more than 940,000 lives in 2022 alone, according to the American Heart Association (AHA). The economic burden is equally staggering: annual health care costs for cardiovascular conditions are forecast to nearly quadruple from $393 billion in 2020 to $1.4 trillion by 2050. Into this escalating crisis steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics, and genetics to detect coronary heart disease earlier and more accurately than traditional methods.
Cardio Diagnostics’ approach centers on a simple blood draw, analyzing epigenetic markers—chemical modifications to DNA that influence gene expression—combined with AI-driven algorithms to identify patients with coronary heart disease, including forms that standard diagnostic tools routinely miss. This capability gives the company a defensible clinical position, as early detection can significantly alter disease progression and reduce long-term healthcare costs. The company’s technology aims to address a critical gap in current cardiovascular diagnostics, which often rely on imaging or stress tests that may not capture early-stage or atypical disease presentations.
The company has been building momentum through recent commercial and regulatory milestones. In a recent press release, Cardio Diagnostics highlighted its progress in expanding access to its epigenetic test, positioning it as a scalable solution for a healthcare system strained by rising cardiovascular disease prevalence. The company’s efforts are particularly relevant given that the AHA reports one person dies from cardiovascular disease every 34 seconds in the U.S., underscoring the urgent need for more effective screening tools.
Investors are taking note of Cardio Diagnostics’ potential to capture a share of a massive market. The company’s stock is traded on the NASDAQ under the ticker CDIO, and more information about its latest developments is available in its newsroom at https://ibn.fm/CDIO. As the healthcare industry grapples with the dual challenges of improving outcomes and controlling costs, Cardio Diagnostics’ AI-driven epigenetic testing represents a promising frontier in the fight against the nation’s number one killer.
